Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
20 - Familial myeloproliferative neoplasms – implications for patients and their families
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 178 - 183Publisher: Cambridge University PressPrint publication year: 2016
References
Delhommeau, F, Dupont, S, Della Valle, V, James, C, Trannoy, S, Masse, A, et al. Mutation in TET2 in myeloid cancers. New England Journal of Medicine. 2009;360(22):2289–301.CrossRefGoogle ScholarPubMed
Schaub, FX, Looser, R, Li, S, Hao-Shen, H, Lehmann, T, Tichelli, A, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003–7.CrossRefGoogle ScholarPubMed
Kralovics, R, Stockton, DW, Prchal, JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102(10):3793–6.CrossRefGoogle ScholarPubMed
Bellanne-Chantelot, C, Chaumarel, I, Labopin, M, Bellanger, F, Barbu, V, De Toma, C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346–52.CrossRefGoogle ScholarPubMed
Rumi, E, Passamonti, F, Della Porta, MG, Elena, C, Arcaini, L, Vanelli, L, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. Journal of Clinical Oncology. 2007;25(35):5630–5.CrossRefGoogle ScholarPubMed
Landgren, O, Goldin, LR, Kristinsson, SY, Helgadottir, EA, Samuelsson, J, Bjorkholm, M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199–204.CrossRefGoogle Scholar
Swierczek, SI, Agarwal, N, Nussenzveig, RH, Rothstein, G, Wilson, A, Artz, A, et al. Hematopoiesis is not clonal in healthy elderly women. Blood. 2008;112(8):3186–93.CrossRefGoogle Scholar
Prchal, JF, Axelrad, AA. Letter: Bone-marrow responses in polycythemia vera. New England Journal of Medicine. 1974;290(24):1382.Google ScholarPubMed
Kapralova, K, Lanikova, L, Lorenzo, F, Song, J, Horvathova, M, Divoky, V, et al. RUNX1 and NF-E2 upregulation is not specific for MPNs, but is seen in polycythemic disorders with augmented HIF signaling. Blood. 2014;123(3):391–4.CrossRefGoogle Scholar
Levine, RL, Pardanani, A, Tefferi, A, Gilliland, DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nature Reviews Cancer. 2007;7(9):673–83.CrossRefGoogle ScholarPubMed
Kralovics, R, Guan, Y, Prchal, JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology. 2002;30(3):229–36.CrossRefGoogle ScholarPubMed
Yildirim, E, Kirby, JE, Brown, DE, Mercier, FE, Sadreyev, RI, Scadden, DT, et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell. 2013;152(4):727–42.CrossRefGoogle ScholarPubMed
Spivak, JL, Considine, M, Williams, DM, Talbot, CC, Jr., Rogers, O, Moliterno, AR, et al. Two clinical phenotypes in polycythemia vera. New England Journal of Medicine. 2014;371(9):808–17.CrossRefGoogle ScholarPubMed
Ranjan, A, Penninga, E, Jelsig, AM, Hasselbalch, HC, Bjerrum, OW. Inheritance of the chronic myeloproliferative neoplasms. A systematic review. Clinical Genetics. 2013;83(2):99–107.CrossRefGoogle ScholarPubMed
Saint-Martin, C, Leroy, G, Delhommeau, F, Panelatti, G, Dupont, S, James, C, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628–32.CrossRefGoogle ScholarPubMed
Olcaydu, D, Rumi, E, Harutyunyan, A, Passamonti, F, Pietra, D, Pascutto, C, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011;96(3):367–74.CrossRefGoogle ScholarPubMed
Oddsson, A, Kristinsson, SY, Helgason, H, Gudbjartsson, DF, Masson, G, Sigurdsson, A, et al. The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms. Leukemia. 2014;28(6):1371–4.CrossRefGoogle ScholarPubMed
Jager, R, Harutyunyan, AS, Rumi, E, Pietra, D, Berg, T, Olcaydu, D, et al. Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. American Journal of Hematology. 2014;89(12):1107–10.CrossRefGoogle ScholarPubMed
Wang, L, Swierczek, SI, Drummond, J, Hickman, K, Kim, SJ, Walker, K, et al. Whole-exome sequencing of polycythemia vera revealed novel driver genes and somatic mutation shared by T cells and granulocytes. Leukemia. 2014;28(4):935–8.CrossRefGoogle Scholar